СОВРЕМЕННЫЕ ВОЗМОЖНОСТИ ПРИМЕНЕНИЯ АНТИЛЕЙКОТРИЕНОВЫХ ПРЕПАРАТОВ В ЛЕЧЕНИИ БРОНХИАЛЬНОЙ АСТМЫ У ВЗРОСЛЫХ
https://doi.org/10.18093/0869-0189-2014-0-1-91-96
Аннотация
О современных возможностях применения антилейкотриеновых препаратов в лечении бронхиальной астмы у взрослых.
Об авторе
И. А. Баранова
ГОУ ВПО "РНИМУ им. Н.И.Пирогова" Росздрава: 117997, Москва, ул. Островитянова, 1
Россия
д. м. н., профессор кафедры госпитальной терапии педиатрического факультета РГМУ; тел.: (495) 965-45-20
Россия
д. м. н., профессор кафедры госпитальной терапии педиатрического факультета РГМУ; тел.: (495) 965-45-20
Список литературы
1. Curschmann H. Ueber Bronchiolitis exsudative und ihr Verhaltniss zum Asthma nervosum. Dtsch. Arch. Klin. Med. 1882; 32: 1–34.
2. Hay D.W. Pharmacology of leukotriene receptor antagonists. More than inhibitors of bronchoconstriction. Chest 1997; 111 (2, Suppl.): 35S–45S.
3. Lipworth B.J. Leukotriene-receptor antagonists. Lancet 1999; 353 (9146): 57–62.
4. Drazen J.M., Israel E., O'Byrne P.M. Treatment of asthma with drugs modifying the leukotriene pathway. N. Engl. J. Med. 1999; 340 (3): 197–206.
5. Barnes N.C., Miller C.J. Effect of leukotriene receptor antagonist therapy on the risk of asthma exacerbations in patients with mild to moderate asthma: an integrated analysis of zafirlukast trials. Thorax 2000; 55 (6): 478–483.
6. Chauhan B.F., Ducharme F.M. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and / or chronic asthma in adults and children. Cochrane Database Syst. Rev. 2012; 5: CD002314.
7. Глобальная стратегия лечения и профилактики бронхиальной астмы. Пересмотр 2011 г.: Пер. с англ. Под ред. А.С.Белевского. М.: Российское респираторное общество; 2012.
8. Nelson H.S., Busse W.W., Kerwin E. et al. Fluticasone propionate / salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J. Allergy Clin. Immunol. 2000; 106 (6):1088–1095.
9. Fish J.E., Israel E., Murray J.J. et al. Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy. Chest 2001; 120 (2): 423–430.
10. Ringdal N., Eliraz A., Pruzinec R. et al. The salmeterol / fluticasone combination is more effective than fluticasone plus oral montelukast in asthma. Respir. Med. 2003; 97 (3):234–241.
11. Deykin A., Wechsler M.E., Boushey H.A. et al. Combination therapy with a long-acting beta-agonist and a leukotriene antagonist in moderate asthma. Am. J. Respir. Crit. Care Med. 2007; 175 (3): 228–234.
12. Kraft M., Djukanovic R., Wilson S. et al. Alveolar tissue inflammation in asthma. Am. J. Respir. Crit. Care Med. 1996; 154 (5): 1505–1510.
13. Bjermer L. The role of small airway disease in asthma. Curr. Opin. Pulm. Med. 2014; 20 (1): 23–30.
14. Bjermer L. History and future perspectives of treating asthma as a systemic and small airways disease. Respir. Med. 2001; 95 (9): 703–719.
15. Balzar S., Chu H.W., Strand M., Wenzel S. Relationship of small airway chymase-positive mast cells and lung function in severe asthma. Am. J. Respir. Crit. Care Med. 2005; 171 (5): 431–439.
16. Wenzel S.E., Szefler S.J., Leung D.Y. et al. Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids. Am. J. Respir. Crit. Care Med. 1997; 156 (3, Pt 1): 737–743.
17. Chen X., Wang K., Jiang M., Nong G.M. Leukotriene receptor antagonists for small-airway abnormalities in asthmatics: a systematic review and meta-analysis. J. Asthma 2013; 50 (7): 695–704.
18. Yasui H., Fujisawa T., Inui N. et al. Impact of add-on pranlukast in stable asthma; the additive effect on peripheral airway inflammation. Respir. Med. 2012; 106 (4): 508–514.
19. Abdel Aziz R.R., Helaly N.Y., Zalata K.R., Gameil N.M. Influence of inhaled beclomethasone and montelukast on airway remodeling in mice. Inflammopharmacology 2013; 21 (1): 55–66.
20. Bousquet J., Khaltaev N., Cruz A.A. et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008; 63 (Suppl. 86): 8–160.
21. Greisner W.A. 3rd, Settipane R.J., Settipane G.A. Co-existence of asthma and allergic rhinitis: a 23-year follow-up study of college students. Allergy Asthma Proc. 1998; 19 (4): 185–188.
22. Philip G., Nayak A.S., Berger W.E. et al. The effect of montelukast on rhinitis symptoms in patients with asthma and seasonal allergic rhinitis. Curr. Med. Res. Opin. 2004; 20:1549–1558.
23. Busse W.W., Casale T.B., Dykewicz M.S. et al. Efficacy of montelukast during the allergy season in patients with chronic asthma and seasonal aeroallergen sensitivity. Ann. Allergy Asthma Immunol. 2006; 96: 60–68.
24. Price D.B., Swern A., Tozzi C.A. et al. Effect of montelukast on lung function in asthma patients with allergic rhinitis: analysis from the COMPACT trial. Allergy 2006; 61 (6):737–742.
25. Wenzel S.E., Szefler S.J., Leung D.Y. et al. Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids. Am. J. Respir. Crit. Care Med. 1997; 156(3, Pt 1): 737–743.
26. Green R.H., Brightling C.E., Woltmann G. et al. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 2002; 57 (10): 875–879.
27. Barnes P.J. Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. J. Allergy Clin. Immunol. 2013; 131 (3): 636–645. DOI: 10.1016/j.jaci. 2012.12.1564.
28. Thomson N.C., Chaudhuri R. Asthma in smokers: challenges and opportunities. Curr. Opin. Pulm. Med. 2009; 15 (1):39–45.
29. Moore A.R., Willoughby D.A. The role of cAMP regulation in controlling inflammation. Clin. Exp. Immunol. 1995; 101:387–389.
30. Johnson M. Effects of b2-agonists on resident and infiltrating inflammatory cells. J. Allergy Clin. Immunol. 2002; 110 (Suppl.): S282–S290.
31. Tintinger G.R., Theron A.J., Anderson R. et al. Comparison of the effects of selective and non-selective b-adrenergic agonists on the pro-inflammatory activities of human neutrophils in vitro. Inflammation 2000; 24: 239–249.
32. Anderson R., Theron A.J., Gravett C.M. et al. Montelukast inhibits neutrophil pro-inflammatory activity by a cyclic AMP-dependent mechanism. Br. J. Pharmacol. 2009; 156:105–115.
33. Gravett C.M., Theron A.J., Steel H.C. et al. Interactive inhibitory effects of formoterol and montelukast on activated human neutrophils. Eur. Respir. J. 2010; 36 (6):1417–1424.
34. Thomson N.C., Chaudhuri R. Asthma in smokers: challenges and opportunities. Curr. Opin. Pulm. Med. 2009; 15 (1):39–45.
35. Price D., Popov T.A., Bjermer L. et al. Effect of montelukast for treatment of asthma in cigarette smokers. J. Allergy Clin. Immunol. 2013; 131 (3): 763–771.
36. Takemura M., Niimi A., Matsumoto H. et al. Clinical, physiological and anti-inflammatory effect of montelukast in patients with cough variant asthma. Respiration 2012; 83 (4): 308–315.
37. Picado C. Aspirin-intolerant asthma: role of cyclo-oxygenase enzymes. Allergy 2002; Suppl. 72: 58–60.
38. Arm J.P., O'Hickey S.P., Spur B.W., Lee T.H. Airway responsiveness to histamine and leukotriene E4 in subjects with aspirin-induced asthma. Am. Rev. Respir. Dis. 1989; 140: 148–153.
39. Dahlen S.E., Malmstrom K., Nizankowska E. et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebocontrolled trial. Am. J. Respir. Crit. Care Med. 2002; 165 (1): 9–14.
40. Park J.S., Jang A.S., Park S.W. et al. Protection of leukotriene receptor antagonist against aspirin-induced bronchospasm in asthmatics. Allergy Asthma Immunol. Res. 2010; 2 (1): 48–54.
41. Schäper C., Noga O., Koch B. et al. Anti-inflammatory properties of montelukast, a leukotriene receptor antagonist in patients with asthma and nasal polyposis. J. Invest. Allergol. Clin. Immunol. 2011; 21 (1): 51–58.
42. Nonaka M., Sakanushi A., Kusama K. et al. One-year evaluation of combined treatment with an intranasal corticosteroid and montelukast for chronic rhinosinusitis associated with asthma. J. Nippon Med. Sch. 2010; 77 (1): 21–28.
43. de Benedictis F.M., Vaccher S., de Benedictis D. Montelukast sodium for exercise-induced asthma. Drugs Today (Barc). 2008; 44 (11): 845–855.
44. Kaminsky D.A., Bates J.H., Irvin C.G. Effects of cool, dry air stimulation on peripheral lung mechanics in asthma. Am. J. Respir. Crit. Care Med. 2000;162 (1): 179–186.
45. Kemp J.P., Dockhorn R.J., Busse W.W. et al. Prolonged effect of inhaled salmeterol against exercise-induced bronchospasm. Am. J. Respir. Crit. Care Med. 1994; 150 (6, Pt 1):1612–1615.
46. de Benedictis F.M., Vaccher S., de Benedictis D. Montelukast sodium for exercise-induced asthma. Drugs Today (Barc) 2008; 44 (11): 845–855.
47. Villaran C., O'Neill S.J., Helbling A. et al. Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction. Montelukast / Salmeterol Exercise Study Group. J. Allergy Clin. Immunol. 1999; 104 (3, Pt 1):547–553.
48. Edelman J.M., Turpin J.A., Bronsky E.A. et al. Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction. A randomized, doubleblind trial. Exercise Study Group. Ann. Intern. Med. 2000; 132 (2): 97–104.
49. Storms W., Chervinsky P., Ghannam A.F. et al. A comparison of the effects of oral montelukast and inhaled salmeterol on response to rescue bronchodilation after challenge. Respir. Med. 2004; 98 (11): 1051–1062.
50. Camargo C.A. Jr, Gurner D.M., Smithline H.A. et al. A randomized placebo-controlled study of intravenous montelukast for the treatment of acute asthma. J. Allergy Clin. Immunol. 2010; 125 (2): 374–380.
51. Watts K., Chavasse R.J. Leukotriene receptor antagonists in addition to usual care for acute asthma in adults and children. Cochrane Database Syst. Rev. 2012; 5: CD006100.
52. Wilson S.R., Strub P., Buist A.S. et al. Shared treatment decision making improves adherence and outcomes in poorly controlled asthma. Am. J. Respir. Crit. Care Med. 2010; 181: 566–577.
53. Storms W., Michele T.M., Knorr B. et al. Clinical safety and tolerability of montelukast, a leukotriene receptor antagonist, in controlled clinical trials in patients aged > or = 6 years. Clin. Exp. Allergy 2001; 31 (1): 77–87.
54. Bakhireva L.N., Jones K.L., Schatz M. et al. Safety of leukotriene receptor antagonists in pregnancy. J. Allergy Clin. Immunol. 2007; 119 (3): 618–625.
55. Sarkar M., Koren G., Kalra S. et al. Montelukast use during pregnancy: a multicentre, prospective, comparative study of infant outcomes. Eur. J. Clin. Pharmacol. 2009; 65 (12):1259–1264.
Рецензия
Для цитирования:
Баранова И.А. СОВРЕМЕННЫЕ ВОЗМОЖНОСТИ ПРИМЕНЕНИЯ АНТИЛЕЙКОТРИЕНОВЫХ ПРЕПАРАТОВ В ЛЕЧЕНИИ БРОНХИАЛЬНОЙ АСТМЫ У ВЗРОСЛЫХ. Пульмонология. 2014;(1):91-96. https://doi.org/10.18093/0869-0189-2014-0-1-91-96
For citation:
Baranova I.A. CURRENT ADMINISTRATION OF ANTILEUKOTRIENES IN ADULTS WITH ASTHMA. PULMONOLOGIYA. 2014;(1):91-96. (In Russ.) https://doi.org/10.18093/0869-0189-2014-0-1-91-96
Просмотров:
1082
Послать статью по эл. почте 